Last updated: 11/03/2018 22:24:12

New method using deuterium labelled creatine to measure total body skeletal muscle mass

GSK study ID
202600
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Total body skeletal muscle mass estimation by creatine (methyl-d3) dilution in athletes
Trial description: Creatine (methyl-d3) dilution (D3-creatine) is a novel technique for the estimation of muscle mass. The method uses a dose of deuterium-labelled creatine to determine total skeletal muscle mass via estimation of total body creatine pool size.The aim of this study is to compare estimates of total body skeletal muscle mass by D3-creatine dilution method and whole body Magnetic Resonance Imaging (MRI) in an athletic population.
Primary purpose:
Basic Science
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Not applicable
Primary outcomes:

Correlation between muscle mass obtained by MRI method and D3-Creatine method

Timeframe: Upto 3 months

Secondary outcomes:
Not applicable
Interventions:
  • Dietary supplement: D3 Creatine
  • Dietary supplement: Creatine
  • Enrollment:
    20
    Primary completion date:
    Not applicable
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Sports Nutritional Sciences
    Product
    Not applicable
    Collaborators
    Not applicable
    Study date(s)
    October 2014 to January 2015
    Type
    Interventional
    Phase
    Not applicable

    Participation criteria

    Sex
    Female & Male
    Age
    18 - 40 years
    Accepts healthy volunteers
    Yes
    • Trained and competing elite canoe athletes will be recruited, who represent Great Britain Canoeing
    • Pregnant and lactating women
    • Intolerance or hypersensitivity to Creatine supplementation

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Brentford, United Kingdom, TW8 9 DA
    Status
    Study Complete

    Study documents

    Statistical analysis plan
    Available language(s): English
    Clinical study report
    Available language(s): English
    Protocol
    Available language(s): English

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    Not applicable
    Actual study completion date
    2015-30-01

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Additional information
    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website